Ipsen : CA T4 2019 et ROC FY 2019 en ligne – Guidances 2022 abaissées – OC abaissé à 69.4 € (vs 83.3 €)
>2019 bon mais conforme – Perspectives 2022 abaissées de >12% - Le CA T4 est en hausse de 16.1% (701.9 M€) et de 16.2% à tcc. Sur l’année, le CA atteint 2 576.2 M€ (+15.8% et +14.8% à tcc. – CS : 2 559 M€e). Le ROC se monte à 782.6 M€, soit 30.4% du CA (CS : 778 M€e). La suspension du programme palovarotène entraine une perte de valeur de 669 M€ av. IS. : le BN ressort à -50 M€. A titre de guidance 2020, Ipsen indique viser un CA de 2 730 M€, soit +6% (pas de split en...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.